ArticleJournal of cellular and molecular medicine2026
Myeloid-Derived Growth Factor Improves Endothelial Progenitor Cell Function and Angiogenesis in Mice With Diabetic Hindlimb Ischemia by Activating Akt/HIF-1α Signalling Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Myeloid-derived growth factor (MYDGF) offers new insights into inflammation and endothelial function, yet its role in endothelial progenitor cells (EPCs) and diabetes-related hindlimb ischemia (DLI) remains unclear. In this study, we found that MYDGF depletion impaired the angiogenic function of EPCs, leading to reduced vascularisation and decreased blood flow in diabetic mice with hindlimb ischemia. Conversely, treatment with adeno-associated virus-mediated MYDGF restored vascularisation and improved blood perfusion. In vitro, treatment with recombinant MYDGF attenuated EPC dysfunction, apoptosis and inflammatory responses. Mechanistic studies revealed that these protective effects were mediated via the AKT/HIF-1α pathway, and silencing HIF-1α abrogated the benefits of MYDGF both in vivo and in vitro. Together, these findings identified MYDGF as a potential therapeutic target for DLI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.